Deal abstention ahead if Valeant's $2.6bn bid for Medicis proceeds
This article was originally published in Scrip
Acquisitive Valeant Pharmaceuticals International will have to put its big ticket purchases on hold for 12 months if it succeeds in pulling off its planned $2.6 billion acquisition of US dermatology and aesthetics firm Medicis.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.